01 / THE ARGUMENT
Precision is also a delivery property
A cardiovascular-kidney-metabolic strategy can identify the right patient and still fail to deliver care. A missing urine test, an unaffordable prescription, an uncompleted referral or an unresolved handoff can interrupt the same pathway. My thesis is that precision CKM care should describe both biological need and delivery feasibility. The purpose of the latter is to fund the response to barriers, not to classify patients with difficult circumstances as commercially unattractive.
The AHA presidential advisory frames CKM health as the interaction of metabolic risk, kidney disease and cardiovascular health, with attention to life-course prevention, social determinants and interdisciplinary care. That is a clinical and organizational framework rather than evidence that a new coordination platform reduces costs. For an executive, its significance is that separate disease budgets may be funding fragments of a common patient journey. The allocation unit should be an accountable care decision and the capacity to execute it. [1]
02 / THE ARGUMENT
Map eligibility and the missing step separately
Pohlman and colleagues’ 2025 review synthesizes protective medication evidence and emphasizes equitable distribution and more precise therapeutic approaches. It supports the importance of connecting clinical advances with access; it does not supply a universal ordering of every available intervention. KDIGO separately organizes kidney assessment around cause, filtration and albuminuria. Together, these sources argue for clinically grounded assessment before a commercial program labels a population eligible or calculates its addressable opportunity. [2,3]
Build two linked records. The clinical record captures validated measures, disease stage, comorbidities, current therapy and the clinician’s decision. The delivery record identifies the next necessary step, its owner, its deadline and the reason it has not occurred. A missing laboratory result and an unaffordable medication are different constraints. Treating both as generic nonadherence obscures responsibility and invites a generic intervention that may address neither. Patient preferences and a clinically justified decision to defer remain legitimate pathway outcomes.
03 / THE ARGUMENT
Invest against the constraint
The next dollar should address the constraint that prevents the next appropriate decision. If incomplete assessment dominates, buy laboratory access and reliable result follow-up. If clinically suitable therapy is selected but not started, examine benefit design, authorization and pharmacy fulfillment. If complex disease exceeds available specialist capacity, redesign consult routing and escalation. Buying more analytics while the unresolved queue grows improves visibility without increasing throughput. Conversely, adding clinicians may be wasteful when the real problem is an incomplete referral packet.
This is a business allocation hypothesis, not a clinical scoring formula. Management can compare pathways using eligible need, the documented gap, achievable completion, resource requirements and a stated clinical horizon. Clinicians determine suitability and urgency. Finance makes costs explicit. Equity review prevents an easy-to-reach population from crowding out patients who need more navigation or interpretation support. The plan should specify extra capacity for those barriers rather than silently penalize them through a low predicted engagement score.
04 / THE ARGUMENT
Make the handoff a funded obligation
A referral is not a completed service. A CKM pathway needs a sending owner, a receiving owner and a documented endpoint: assessment completed, treatment initiated, another clinically appropriate plan, or a clearly explained unresolved barrier. A shared queue can make these obligations visible, but a queue alone cannot create a payer agreement, specialist appointment or community service. Service-line and partner contracts should name the responsibilities that existing reimbursement leaves unclear.
The strongest use of automation is administrative reliability: assemble the permitted referral information, detect a missing result, surface overdue follow-up and preserve the reason for closure. Risk interpretation, diagnosis and treatment remain accountable clinical decisions. A model should not infer poverty, disability or household circumstances from an opaque proxy and use that inference to restrict care. Use information patients provide and authorized records for defined purposes; offer a correction path when an operational record misrepresents their needs.
05 / THE ARGUMENT
Measure equity at every transition
An overall completion rate can rise while a subgroup falls further behind. Review the pathway from assessment through treatment and follow-up by relevant demographic and access characteristics, subject to reliable data and appropriate governance. Separate differences in eligibility from differences in delivery. A group with fewer completed referrals may have more severe barriers, incomplete records or different preferences; the data should trigger investigation, not a causal conclusion about the group. Financial results also need a defined counterfactual before they become savings claims.
Scale when the program demonstrates dependable assessment, accountable closure and a credible ability to serve the population it claims to cover. If the intervention advances easy cases while unresolved high-need patients accumulate, the remedy is an allocation change. The strategic goal is a repeatable way to translate established clinical opportunities into feasible care. That requires clinical judgment, pharmacy execution, community capacity and financing to be planned together, with uncertainty made explicit at the investment decision.
FROM EVIDENCE TO ALLOCATION
The operating and investment case
Proposed design by Azis R. Dabas. These decisions and evaluation criteria are not outcomes established by the cited studies.
- Decision
- Choose the next CKM investment by the clinically justified care step that is failing, with explicit resources for access barriers. Compare assessment, medication access and specialist capacity before purchasing another identification tool.
- Accountable owner
- An accountable CKM service-line leader, working with primary care, cardiology, nephrology, pharmacy, community partners and a finance sponsor. Each referred patient retains a named clinical owner.
The delivery sequence
- Establish clinical need using documented assessments and applicable guidance.
- Record the next appropriate decision and the patient’s preferences.
- Identify the specific access or capacity barrier and assign its resolution.
- Complete the handoff or document an appropriate alternative and unresolved reason.
- Review transition-level equity, safety, capacity and expenditure before reallocating the next investment.
The economics
Estimate the incremental cost of resolving each documented pathway constraint, including staff, appointments, medication support and follow-up. Compare cost per completed appropriate decision without assuming that every closure avoids an admission. Evaluate downstream outcomes separately using a suitable comparator and observation period.
The measures that govern expansion
- Completeness of clinically required assessment
- Time to clinically appropriate treatment decision
- Referral closure with documented receiving owner
- Unresolved barriers and aging of the high-need queue
- Transition-level access differences and corrective actions
- Actual pathway cost and staffed capacity utilization
Stop or redesign when
Pause expansion if referrals exceed safe receiving capacity, if data cannot distinguish clinical deferral from access failure, or if selection systematically favors patients who are easiest to contact rather than patients prioritized by clinical need.
THE EVIDENCE LEDGER
What supports the argument
Study findings, policy requirements and market signals support different claims. Their boundaries remain visible.
[1] policy · October 9, 2023
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association
- Design or status
- Presidential advisory; online October 9, 2023, November 14 issue
- Verified finding
- Defines a CKM framework spanning disease staging, prediction, life-course prevention, social determinants and interdisciplinary care.
- Boundary
- An advisory is not a comparative trial of a particular care model. A correction was published in March 2024; the publisher record should be consulted for implementation.
[2] peer-reviewed · May 19, 2025
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
- Design or status
- Narrative review; online May 19, 2025, August 2025 issue
- Verified finding
- Synthesizes SGLT2-inhibitor and GLP-1-receptor-agonist evidence and emphasizes equitable pharmacotherapy distribution and tailored CKM interventions.
- Boundary
- The review does not test a capital-allocation model or establish the causal effect of an access intervention.
[3] policy · April 2024
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
- Design or status
- Clinical guideline.
- Verified finding
- CKD classification uses cause, GFR and albuminuria.
- Boundary
- Not a local implementation ROI study.
FOLLOW THE SOURCE
Sources and editorial method
Selected evidence was reviewed through October 7, 2026. Numbered references connect claims to their underlying records. Economic mechanisms and business cases are the author’s analysis unless a source is cited. The review is selective; publication dates retain the precision available in the source.
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association
Chiadi E. Ndumele, Janani Rangaswami, Sheryl L. Chow, Ian J. Neeland, Katherine R. Tuttle, Sadiya S. Khan, Josef Coresh, American Heart Association Writing Committee. Circulation. . policy.
DOI: 10.1161/CIR.0000000000001184 · Primary verification record
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Neal Pohlman, Prem N. Patel, Utibe R. Essien, Jasmyn J. Tang, Joshua J. Joseph. The Journal of Clinical Endocrinology & Metabolism. . peer-reviewed.
DOI: 10.1210/clinem/dgaf295 · Primary verification record · Consensus paper record
Consensus citation count at retrieval: 24. This dated index count is not a measure of study quality.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
KDIGO CKD Work Group. Kidney International. . policy.
DOI: 10.1016/j.kint.2023.10.018 · Primary verification record
Study authors retain credit for their work. Researcher affiliations and publisher names do not imply affiliation with or endorsement of this analysis.